Penumbra’s FDA nod for clot removal tech a win for Boston Scientific
Source ↗
👁 6
💬 0
The stroke treatment could contribute about $100 million in incremental revenue over time to Boston Scientific, the buyer of Penumbra, one analyst said.
Comments (0)